WhiteOak Capital Pharma and Healthcare Fund
WhiteOak Capital Mutual Fund · Best Sectoral & Thematic Mutual Funds
This is the Regular plan of WhiteOak Capital Pharma and Healthcare Fund — bought through a distributor, whose commission is paid out of its expense ratio. Income is retained in the fund, so it shows up as NAV rather than as a payout.
Performance
Scorecard
★★★★★5/5 vs 238 of 257 Sectoral/ Thematic peers1Y- Performance 60%
- Risk 15%
- Cost 10%
- Downside 15%
How this is computed
Each verdict is computed from this fund's own metrics against its sub-category — the number behind it is shown, not a black-box rating. The stars weight the same ground 60/15/10/15 (performance/risk/cost/downside) across every fund in the peer group. Ranked within Sectoral/ Thematic (same plan and option). Based on a 1-year record — this fund is too young for a 3-year CAGR, so its performance is ranked on 1Y against the same peers. 238 of the 257 Sectoral/ Thematic funds in this cohort carry the full record the stars need, so they are the ones ranked against.
No 3-year record to rank on yet
Volatility 14.5% vs 15.8% category avg
2.7% expense vs 2.5% category avg
Not enough history for a rolling 3Y view
Strengths & concerns
Generated from this fund's own numbers against its sub-category — each point names the figure behind it.
Strengths
- Ahead of the Sectoral/ Thematic average on 1M/3M/6M/1Y — 1Y by 19.67pp
- Ranks #8 of 238 on 1-year return in its Sectoral/ Thematic cohort
Concerns
- High expense ratio (2.74%) vs the Sectoral/ Thematic average of 2.45%
Key Metrics
Scheme Info
DefinitionsPeriod returns (<1Y, absolute — not annualized)
DefinitionsAnnualized returns (≥1Y — CAGR)
DefinitionsAdvanced metrics — risk and benchmark ratios
Fund vs category average (Sectoral/ Thematic)
| Period | Fund | Category avg. | Diff |
|---|---|---|---|
| 1M abs | +11.21% | +6.04% | +5.17% |
| 3M abs | +4.49% | +0.25% | +4.24% |
| 6M abs | +15.56% | +7.28% | +8.28% |
| 1Y CAGR | +24.05% | +4.38% | +19.67% |
| 3Y CAGR | — | +13.04% | — |
| 5Y CAGR | — | +11.76% | — |
Category average across peers in Sectoral/ Thematic (up to 257 funds with data), same plan and option, excluding this fund. Under-1-year figures are absolute; 1Y and beyond are annualised (CAGR).
Not sure what a figure means? The glossary explains every metric, and the methodology shows the formulas.
Category rank
Vs 257 peers in Sectoral/ Thematic
Backtest this fund
What a SIP or one-time investment would have grown to over this fund’s real NAV history.
12 monthly installments of ₹10,000 into WhiteOak Capital Pharma and Healthcare Fund, valued at the latest NAV. XIRR annualizes for each installment’s timing.
Calendar-year returns
What the fund actually returned in each year, not the smoothed average.
| Year | Fund | Nifty Healthcare TRI | Diff | |
|---|---|---|---|---|
| 2026part | +27.28% | +19.00% | +8.28% | |
| 2025 | +0.09% | -1.53% | +1.62% | |
| 2024part | +36.24% | — | — |
January–December, from this fund's NAV history. Absolute return, not annualised. “part” marks a year the fund didn't run end to end — its first year, the current year so far, or one it stopped reporting in; those years show no benchmark comparison.
Taxation
Taxed as equityThis is an equity-oriented fund (≥65% in Indian equities), so gains get the concessional capital-gains rates below — they do not add to your income-tax slab.
Flat, on the whole gain
On gains above ₹1.25 L per financial year
Applies to capital gains on redemption. Excludes IDCW/dividend tax, STT, surcharge and cess, and pre-2018 equity grandfathering. For research only — consult a tax advisor before filing.
Asset allocation
As on 30 Sep 2026 · AMC disclosure- Equity90.72%
- Cash & Equivalents6.13%
- Debt3.15%
AMC Profile
WhiteOak Capital Mutual Fund is run by WhiteOak Capital Asset Management, founded by Prashant Khemka, previously chief investment officer of Goldman Sachs' India equity business. The house entered mutual funds by acquiring YES Mutual Fund in 2021 and now runs a broad equity and hybrid range.
Fund Managers
PBPiyush BaranwalStart date not disclosed
Senior Fund Manager
Bachelor of Engineering, PGDBM, clearedall 3 levels of CFA
Over 18 years' experience in Portfolio Management and trading in Fixed Income securities. WhiteOak Capital Asset Management Limited (November 01, 2021 - till date) 2. YES Asset Management (India) Limited (October 22, 2018 – October 31, 2021) 3. BOI AXA Investment Managers (July 2014 - October 19, 2018)
- WhiteOak Capital Aggressive Hybrid Fund
- WhiteOak Capital Arbitrage Fund
- WhiteOak Capital Balanced Advantage Fund
- WhiteOak Capital Balanced Hybrid Fund
- WhiteOak Capital Banking & Financial Services Fund
- WhiteOak Capital Consumption Opportunities Fund
- WhiteOak Capital Digital Bharat Fund
- WhiteOak Capital Dividend Yield Fund
- WhiteOak Capital ELSS Tax Saver Fund
- WhiteOak Capital Equity Savings Fund
- WhiteOak Capital ESG Best-In-Class Strategy Fund
- WhiteOak Capital Flexi Cap Fund
- WhiteOak Capital Large & Mid Cap Fund
- WhiteOak Capital Large Cap Fund
- WhiteOak Capital Liquid Fund
- WhiteOak Capital Mid Cap Fund
- WhiteOak Capital Multi Asset Allocation Fund
- WhiteOak Capital Multi Cap Fund
- WhiteOak Capital Quality Equity Fund
- WhiteOak Capital Special Opportunities Fund
- WhiteOak Capital Ultra Short Term Fund
AAAshish AgrawalManaging since 06 Jan 2025
PGDM (Finance)
Over 18 years’ of experience in Financial market: 1. WhiteOak Capital Asset Management Limited (August 2022 - till date) 2. Motilal Oswal Asset Management Company Limited (September 2016 – July 2022) 3. Citi Group Global Markets India Pvt Ltd (October 2010 - September 2016) in the last
- WhiteOak Capital Aggressive Hybrid Fund
- WhiteOak Capital Arbitrage Fund
- WhiteOak Capital Balanced Advantage Fund
- WhiteOak Capital Balanced Hybrid Fund
- WhiteOak Capital Banking & Financial Services Fund
- WhiteOak Capital Consumption Opportunities Fund
- WhiteOak Capital Digital Bharat Fund
- Whiteoak capital Diversified Equity Small Cap Active FOF
- WhiteOak Capital Dividend Yield Fund
- WhiteOak Capital ELSS Tax Saver Fund
- WhiteOak Capital Equity Savings Fund
- WhiteOak Capital ESG Best-In-Class Strategy Fund
- WhiteOak Capital Flexi Cap Fund
- WhiteOak Capital Large & Mid Cap Fund
- WhiteOak Capital Large Cap Fund
- WhiteOak Capital Mid Cap Fund
- WhiteOak Capital Multi Asset Allocation Fund
- WhiteOak Capital Multi Cap Fund
- WhiteOak Capital Quality Equity Fund
- WhiteOak Capital Special Opportunities Fund
RMRamesh MantriStart date not disclosed
CIO - Equities
MBA, CFA
Over 20 years' experience in Financial market: 1. WhiteOak Capital Asset Management Limited (December 21, 2021 - till date) 2. White Oak Capital Management (June 2017 – December 20, 2021) 3. Ashoka Capital Advisers (February 2013 - May 2017)
- WhiteOak Capital Aggressive Hybrid Fund
- WhiteOak Capital Arbitrage Fund
- WhiteOak Capital Balanced Advantage Fund
- WhiteOak Capital Balanced Hybrid Fund
- WhiteOak Capital Banking & Financial Services Fund
- WhiteOak Capital Consumption Opportunities Fund
- WhiteOak Capital Digital Bharat Fund
- WhiteOak Capital Dividend Yield Fund
- WhiteOak Capital ELSS Tax Saver Fund
- WhiteOak Capital Equity Savings Fund
- WhiteOak Capital ESG Best-In-Class Strategy Fund
- WhiteOak Capital Flexi Cap Fund
- WhiteOak Capital Large & Mid Cap Fund
- WhiteOak Capital Large Cap Fund
- WhiteOak Capital Mid Cap Fund
- WhiteOak Capital Multi Asset Allocation Fund
- WhiteOak Capital Multi Cap Fund
- WhiteOak Capital Quality Equity Fund
- WhiteOak Capital Special Opportunities Fund
DPDheeresh PathakStart date not disclosed
PGDBM, BE Fund (Electronics & Communication Engineering)
Over 16 years’ of experience in Financial Market: 1. WhiteOak Capital Asset Management Limited (June, 2022 - till date) 2. Goldman Sachs (April 2007 - June 2021)
- WhiteOak Capital Aggressive Hybrid Fund
- WhiteOak Capital Balanced Advantage Fund
- WhiteOak Capital Balanced Hybrid Fund
- WhiteOak Capital Banking & Financial Services Fund
- WhiteOak Capital Consumption Opportunities Fund
- WhiteOak Capital Digital Bharat Fund
- WhiteOak Capital Dividend Yield Fund
- WhiteOak Capital ELSS Tax Saver Fund
- WhiteOak Capital Equity Savings Fund
- WhiteOak Capital ESG Best-In-Class Strategy Fund
- WhiteOak Capital Flexi Cap Fund
- WhiteOak Capital Large & Mid Cap Fund
- WhiteOak Capital Large Cap Fund
- WhiteOak Capital Mid Cap Fund
- WhiteOak Capital Multi Asset Allocation Fund
- WhiteOak Capital Multi Cap Fund
- WhiteOak Capital Quality Equity Fund
- WhiteOak Capital Special Opportunities Fund
TATrupti AgarwalManaging since 20 May 2025
Fund Manager for Overseas Investments
B.Com, CA Fund
Over 16 years of experience.: 1. WhiteOak Capital Asset Management Limited (December 21, 2021 - till date) 2. WhiteOak Capital (July 2017 – December 20, 2021) 3. Khoob Saree (December 2015 - March 2017)
- WhiteOak Capital Aggressive Hybrid Fund
- WhiteOak Capital Balanced Advantage Fund
- WhiteOak Capital Balanced Hybrid Fund
- WhiteOak Capital Banking & Financial Services Fund
- WhiteOak Capital Consumption Opportunities Fund
- WhiteOak Capital Digital Bharat Fund
- WhiteOak Capital Dividend Yield Fund
- WhiteOak Capital ELSS Tax Saver Fund
- WhiteOak Capital Equity Savings Fund
- WhiteOak Capital ESG Best-In-Class Strategy Fund
- WhiteOak Capital Flexi Cap Fund
- WhiteOak Capital Large & Mid Cap Fund
- WhiteOak Capital Large Cap Fund
- WhiteOak Capital Mid Cap Fund
- WhiteOak Capital Multi Asset Allocation Fund
- WhiteOak Capital Multi Cap Fund
- WhiteOak Capital Quality Equity Fund
- WhiteOak Capital Special Opportunities Fund
Fund manager, benchmark and dealing terms from this scheme's SEBI-filed Scheme Information Document on AMFI. Each manager's qualifications and role are reconciled across every filing this fund house makes for them, including its Statement of Additional Information. Total AUM via AMFI.
Explore from here
WhiteOak Capital in the news
Headlines about the fund house, not this scheme in particular — highlights only; tap through to read the full story at the source.
Midcap SIPs outperform largecap and smallcap funds with over 17% average returns in 10 years: WhiteOak Cap
The Economic Times · 1d ago
Crystal Crop Protection IPO opens on November 18; GMP at ₹19. Check price band, lot size
CNBC TV18 · 1d ago
Large-Cap Vs Mid-Cap Vs Small-Cap SIP: Which Delivered The Highest Returns In 30 Years?
ETV Bharat · 3d ago
WhiteOak MF explains whether to continue an SIP after a weak start
CNBC TV18 · 19 Oct 2026
YES Mutual Fund is Now WhiteOak Capital: Full AMC Guide 2026
Value Research · 06 Jul 2026
WhiteOak Capital Mutual Fund Launches New Fund: WhiteOak Capital Special Opportunities Fund
Upstox · 15 May 2024
WhiteOak Capital Mutual Fund launches WhiteOak Capital Mid Cap Fund
Value Research · 24 Aug 2022
WhiteOak Capital Mutual Fund
Value Research · 18 Jan 2022
Returns and risk are computed from NAV history and may differ slightly from other portals due to methodology (rolling vs point-to-point, dividend treatment). For research only — not investment advice.
About Sectoral & Thematic funds
Sectoral and thematic funds must keep at least 80% in the equity of one sector (banking, pharma, technology) or one theme (consumption, manufacturing, ESG). That concentration is the point and the risk: with no mandate to diversify away from the sector, the fund rises and falls with it.
Frequently asked questions
What is the NAV of WhiteOak Capital Pharma and Healthcare Fund?
As of 19 Nov 2026, the NAV of WhiteOak Capital Pharma and Healthcare Fund is ₹17.48 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.
What returns has WhiteOak Capital Pharma and Healthcare Fund delivered?
WhiteOak Capital Pharma and Healthcare Fund has returned +24.05% over 1 year and +21.92% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.
What is the expense ratio of WhiteOak Capital Pharma and Healthcare Fund?
WhiteOak Capital Pharma and Healthcare Fund charges an expense ratio of 2.74% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.
What are the top holdings of WhiteOak Capital Pharma and Healthcare Fund?
WhiteOak Capital Pharma and Healthcare Fund's largest holdings are Divi's Laboratories Limited (8.4%), Sun Pharmaceutical Industries Limited (7.1%), Torrent Pharmaceuticals Limited (6.3%), Laurus Labs Limited (3.9%) and Apollo Hospitals Enterprise Limited (3.8%). Holdings are disclosed monthly and change over time.
How risky is WhiteOak Capital Pharma and Healthcare Fund?
WhiteOak Capital Pharma and Healthcare Fund sits at the very high level on our estimate of SEBI's risk-o-meter scale, its trailing-3Y volatility (annualised) is 14.5% and its worst peak-to-trough fall in our sample was 15.6%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.
What is the benchmark of WhiteOak Capital Pharma and Healthcare Fund?
WhiteOak Capital Pharma and Healthcare Fund is benchmarked against the BSE Healthcare TRI. The alpha, beta and capture figures on this page are measured against the Nifty Healthcare TRI, the closest index whose daily history we hold.
Who manages WhiteOak Capital Pharma and Healthcare Fund?
WhiteOak Capital Pharma and Healthcare Fund is managed by Piyush Baranwal, Ashish Agrawal, Ramesh Mantri, Dheeresh Pathak and Trupti Agarwal at WhiteOak Capital.
When was WhiteOak Capital Pharma and Healthcare Fund launched, and what is its objective?
WhiteOak Capital Pharma and Healthcare Fund was launched on 06 Feb 2024. its stated objective is: To provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved. Both are as filed in the scheme's own Scheme Summary Document.
How is WhiteOak Capital Pharma and Healthcare Fund taxed?
WhiteOak Capital Pharma and Healthcare Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.